ZA202201652B - Erbb receptor inhibitors - Google Patents

Erbb receptor inhibitors

Info

Publication number
ZA202201652B
ZA202201652B ZA2022/01652A ZA202201652A ZA202201652B ZA 202201652 B ZA202201652 B ZA 202201652B ZA 2022/01652 A ZA2022/01652 A ZA 2022/01652A ZA 202201652 A ZA202201652 A ZA 202201652A ZA 202201652 B ZA202201652 B ZA 202201652B
Authority
ZA
South Africa
Prior art keywords
receptor inhibitors
erbb receptor
erbbs
her2
compounds
Prior art date
Application number
ZA2022/01652A
Inventor
Zhengtao Li
Wei Zhong
Jiabing Wang
Qingbei Zeng
Honchung Tsui
Zhenfan Yang
Xiaolin Zhang
Original Assignee
Dizal Jiangsu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal Jiangsu Pharmaceutical Co Ltd filed Critical Dizal Jiangsu Pharmaceutical Co Ltd
Publication of ZA202201652B publication Critical patent/ZA202201652B/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are compounds inhibiting ErbBs (e. g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.
ZA2022/01652A 2018-05-08 2022-02-08 Erbb receptor inhibitors ZA202201652B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2018085998 2018-05-08

Publications (1)

Publication Number Publication Date
ZA202201652B true ZA202201652B (en) 2026-03-25

Family

ID=99168875

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/01652A ZA202201652B (en) 2018-05-08 2022-02-08 Erbb receptor inhibitors

Country Status (1)

Country Link
ZA (1) ZA202201652B (en)

Similar Documents

Publication Publication Date Title
MX2023008954A (en) Erbb receptor inhibitors.
MX2023010411A (en) Erbb/btk inhibitors.
NZ775660A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2025002170A (en) Kras g12c inhibitors
NZ763551A (en) Compounds useful for inhibiting cdk7
PH12021552482A1 (en) Compounds targeting prmt5
MX2020007797A (en) Gcn2 inhibitors and uses thereof.
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
SA520411524B1 (en) Bisamide sarcomere activating compounds and uses thereof
NZ752250A (en) Compounds, devices, and uses thereof
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
MX2020011542A (en) Cd73 inhibitors.
MX2020010942A (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy.
GEAP202415883A (en) Macrocyclic compounds as sting agonists and methods and uses thereof
PH12021552513A1 (en) Pyrrole compounds
ZA202006071B (en) Antiproliferation compounds and uses thereof
MX2021007247A (en) Rapamycin derivatives.
EA201891578A1 (en) COMPOSITIONS OF 2- (4-CHLOROPHENIL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-IL) -1-OXYOISOINDOLIN-5-IL) METHYL-2,2-DIPHTORACETAMIDE
PH12021552953A1 (en) Tricyclic compounds
PH12019550154B1 (en) Azetidine derivative
ZA202201652B (en) Erbb receptor inhibitors
PH12021550323A1 (en) Dendrimer formulations
ZA202105708B (en) Erbb/btk inhibitors
MX2022007625A (en) Combinations.